STAT3 and non-small cell lung carcinoma: Given the co-activation of NF-κB and STAT3 (two dominant pathways in inflammation and tumorgenesis) (He and Karin, 2011; Fan et al., 2013), small molecule inhibitors targeting them or the upstream receptors merit investigation for combination therapy for NSCLC.